PrEP acceptability and initiation among women engaged in sex work in Uganda: Implications for HIV prevention.
FSW
PrEP
Pre-exposure prophylaxis
Sex work
Stigma
Journal
EClinicalMedicine
ISSN: 2589-5370
Titre abrégé: EClinicalMedicine
Pays: England
ID NLM: 101733727
Informations de publication
Date de publication:
Feb 2022
Feb 2022
Historique:
received:
27
09
2021
revised:
21
12
2021
accepted:
13
01
2022
entrez:
7
2
2022
pubmed:
8
2
2022
medline:
8
2
2022
Statut:
epublish
Résumé
Women engaged in sex work (WESW) are disproportionately affected by HIV. In Uganda, HIV prevalence among WESW is estimated at 37%, accounting for 18% of all new infections in the country. WESW experience poverty, gender-based violence, and other issues that reduce their power and limit their ability to negotiate condom use. Female-controlled strategies, including pre-exposure prophylaxis (PrEP), may afford women more transmission protection, but barriers to access and use persist. This cross-sectional study examined baseline PrEP acceptability and initiation among WESW recently enrolled in a randomized clinical trial in Uganda to test the impact of a combination HIV risk reduction and economic empowerment intervention on sexual risk outcomes (clinicaltrials.gov, NCT03583541). A total of 542 WESW from 19 high HIV-prevalent geographical areas were enrolled in the Kyaterekera study between June 2019 and March 2020. Women were eligible for the study if they: (1) were age 18 or over; (2) reported engagement in transactional sex (a sex act in exchange for pay) in the past 30 days; and (3) reported engagement in one or more episodes of unprotected sex in the past 30 days. Women completed a baseline assessment, were tested for HIV and other sexually transmitted infections (STIs) at enrollment, and were connected with antiretroviral therapy (ART), STI treatment, or PrEP, based on need and interest. Descriptive statistics examined baseline data on PrEP acceptability and initiation. Independent variables (i.e. years in sex work, recent sexual coercion, perceived HIV and sex work stigmas, harmful alcohol use, barriers to medical care, and social support) were derived from the empirical literature and women's self-report. Bivariate analysis was performed to test associations between main effects of these variables. Using binomial logistic regression, predictive models were evaluated for two distinct outcomes-PrEP acceptability and PrEP initiation/uptake. At baseline, 59% of women ( Despite endorsing PrEP use, many WESW remain reluctant to use it. This gap in prevention practice highlights the heart of a failing PrEP prevention cascade. Findings point to the important role family and friend support may play in destigmatizing sex work and PrEP use for women. Social and structural-level efforts are needed to improve educational messaging and to integrate positive messaging into health promotion campaigns for women and their families, while also working toward decriminalizing sex work. This paper was made possible with funding from United States National Institute of Mental Health (Grant number: R01MH116768).
Sections du résumé
BACKGROUND
BACKGROUND
Women engaged in sex work (WESW) are disproportionately affected by HIV. In Uganda, HIV prevalence among WESW is estimated at 37%, accounting for 18% of all new infections in the country. WESW experience poverty, gender-based violence, and other issues that reduce their power and limit their ability to negotiate condom use. Female-controlled strategies, including pre-exposure prophylaxis (PrEP), may afford women more transmission protection, but barriers to access and use persist. This cross-sectional study examined baseline PrEP acceptability and initiation among WESW recently enrolled in a randomized clinical trial in Uganda to test the impact of a combination HIV risk reduction and economic empowerment intervention on sexual risk outcomes (clinicaltrials.gov, NCT03583541).
METHODS
METHODS
A total of 542 WESW from 19 high HIV-prevalent geographical areas were enrolled in the Kyaterekera study between June 2019 and March 2020. Women were eligible for the study if they: (1) were age 18 or over; (2) reported engagement in transactional sex (a sex act in exchange for pay) in the past 30 days; and (3) reported engagement in one or more episodes of unprotected sex in the past 30 days. Women completed a baseline assessment, were tested for HIV and other sexually transmitted infections (STIs) at enrollment, and were connected with antiretroviral therapy (ART), STI treatment, or PrEP, based on need and interest. Descriptive statistics examined baseline data on PrEP acceptability and initiation. Independent variables (i.e. years in sex work, recent sexual coercion, perceived HIV and sex work stigmas, harmful alcohol use, barriers to medical care, and social support) were derived from the empirical literature and women's self-report. Bivariate analysis was performed to test associations between main effects of these variables. Using binomial logistic regression, predictive models were evaluated for two distinct outcomes-PrEP acceptability and PrEP initiation/uptake.
FINDINGS
RESULTS
At baseline, 59% of women (
INTERPRETATION
CONCLUSIONS
Despite endorsing PrEP use, many WESW remain reluctant to use it. This gap in prevention practice highlights the heart of a failing PrEP prevention cascade. Findings point to the important role family and friend support may play in destigmatizing sex work and PrEP use for women. Social and structural-level efforts are needed to improve educational messaging and to integrate positive messaging into health promotion campaigns for women and their families, while also working toward decriminalizing sex work.
FUNDING
BACKGROUND
This paper was made possible with funding from United States National Institute of Mental Health (Grant number: R01MH116768).
Identifiants
pubmed: 35128367
doi: 10.1016/j.eclinm.2022.101278
pii: S2589-5370(22)00008-6
pmc: PMC8808048
doi:
Banques de données
ClinicalTrials.gov
['NCT03583541']
Types de publication
Journal Article
Langues
eng
Pagination
101278Subventions
Organisme : NIMH NIH HHS
ID : R01 MH116768
Pays : United States
Organisme : NIMH NIH HHS
ID : R25 MH067127
Pays : United States
Organisme : NIMH NIH HHS
ID : R25 MH118935
Pays : United States
Informations de copyright
© 2022 The Author(s).
Déclaration de conflit d'intérêts
We declare no competing interests.
Références
BMC Public Health. 2018 Aug 16;18(1):1020
pubmed: 30115056
PLoS One. 2020 Oct 28;15(10):e0241399
pubmed: 33112907
Lancet. 2018 Aug 25;392(10148):698-710
pubmed: 30037733
PLoS One. 2014 Jan 22;9(1):e86200
pubmed: 24465956
J Acquir Immune Defic Syndr. 2019 May 1;81(1):24-35
pubmed: 30964804
BMC Womens Health. 2019 Aug 17;19(1):111
pubmed: 31419968
J Int AIDS Soc. 2020 Jun;23 Suppl 3:e25527
pubmed: 32602669
J Int AIDS Soc. 2020 Feb;23(2):e25451
pubmed: 32112512
Curr Opin HIV AIDS. 2016 Jan;11(1):27-34
pubmed: 26633639
AIDS Care. 2011 May;23(5):619-27
pubmed: 21293991
Adv Drug Deliv Rev. 2021 Sep;176:113849
pubmed: 34186143
Lancet. 2015 Jan 10;385(9963):172-85
pubmed: 25059938
Am J Public Health. 2015 Mar;105(3):e95-102
pubmed: 25602889
PLoS Med. 2017 Nov 21;14(11):e1002444
pubmed: 29161256
Lancet. 2015 Jan 3;385(9962):72-87
pubmed: 25059942
AIDS Educ Prev. 2017 Apr;29(2):141-153
pubmed: 28467163
Nat Commun. 2020 Feb 18;11(1):773
pubmed: 32071298
AIDS Care. 2021 Jun;33(6):729-735
pubmed: 33043688
Int J STD AIDS. 2020 Oct;31(11):1063-1072
pubmed: 32819210
BMC Int Health Hum Rights. 2017 May 5;17(1):11
pubmed: 28476153
AIDS Behav. 2008 Sep;12(5):772-80
pubmed: 18080830
PLoS One. 2020 Apr 30;15(4):e0228620
pubmed: 32352969
J Int AIDS Soc. 2019 Apr;22(4):e25266
pubmed: 30983147
Glob Public Health. 2021 Apr 21;:1-17
pubmed: 33881949
Lancet HIV. 2020 Mar;7(3):e173-e183
pubmed: 31953184
J Natl Med Assoc. 1999 Aug;91(8):439-46
pubmed: 12656432
AIDS Behav. 2020 May;24(5):1312-1333
pubmed: 31807973